ArticleAPL bioengineering2021
Toward improved
Article in APL bioengineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- 3D Bioprinting and Microfluidic-based Devices for Cancer Detection and Drug Treatment: Focus on Prostate Cancer.Current medicinal chemistry · 2026Review
- Mini-hearts for disease modeling and drug testing - process optimization versus biological functionality.Frontiers in bioengineering and biotechnology · 2025Review
- Modeling of brain tumors usingHeliyon · 2024Review
- Advances in exercise-induced vascular adaptation: mechanisms, models, and methods.Frontiers in bioengineering and biotechnology · 2024Review
- Engineering Heterogeneous Tumor Models for Biomedical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Microphysiological model reveals the promise of memory-like natural killer cell immunotherapy for HIVNature communications · 2023Article
- pH/thermal dual-responsive multifunctional drug delivery system for effective photoacoustic imaging-guided tumor chemo/photothermal therapy.APL bioengineering · 2023Article
- Microphysiological systems for solid tumor immunotherapy: opportunities and challenges.Microsystems & nanoengineering · 2023Review
- Microfluidics in vascular biology research: a critical review for engineers, biologists, and clinicians.Lab on a chip · 2022Review
- Editorial Series conclusion and journal outlook.APL bioengineering · 2022Article
- Microfluidic techniques for isolation, formation, and characterization of circulating tumor cells and clusters.APL bioengineering · 2022Review
- Microfluidic Model to Evaluate Astrocyte Activation in Penumbral Region following Ischemic Stroke.Cells · 2022Article
- A role for microfluidic systems in precision medicine.Nature communications · 2022Review
- Review
- In Vitro Cancer Models: A Closer Look at Limitations on Translation.Bioengineering (Basel, Switzerland) · 2022Review
- Article
- Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations.Cancer cell · 2022Review
- Models of Renal Cell Carcinoma Used to Investigate Molecular Mechanisms and Develop New Therapeutics.Frontiers in oncology · 2022Review
- Toward improved models of human cancer: Two perspectives.APL bioengineering · 2021Article
- Patient-Derived Explants as a Precision Medicine Patient-Proximal Testing Platform Informing Cancer Management.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cancer is a leading cause of death across the world and continues to increase in incidence. Despite years of research, multiple tumors (e.g., glioblastoma, pancreatic cancer) still have limited treatment options in the clinic. Additionally, the attrition rate and cost of drug development have continued to increase. This trend is partly explained by the poor predictive power of traditional
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.